Magenta Therapeutics, Inc.
Compositions and methods for the depletion of CD137+ cells
Last updated:
Abstract:
The invention provides methods of preventing and treating graft-versus-host-disease and autoimmune diseases, such as those arising from transplant therapy, by selective depletion of hematopoietic cells through the use of antibody-drug conjugates and ligand-drug conjugates that specifically bind CD137. The compositions and methods described herein can be used to treat a variety of pathologies, including stem cell disorders and other blood conditions.
Status:
Grant
Type:
Utility
Filling date:
19 Jan 2018
Issue date:
3 Mar 2020